Citadel Advisors’s Palvella Therapeutics PVLA Stock Holding History

Citadel Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.52M	Buy	+28,200	New	+$2.94M	﹤0.01%	4946
2024 Q1	–	Sell	-810	Closed	-$11.8K	–	15598
2023 Q4	$11.8K	Buy	810 +4	+0.5%	+$73	﹤0.01%	13023
2023 Q3	$19.2K	Sell	806 -649	-45%	-$13.9K	﹤0.01%	12658
2023 Q2	$19.3K	Buy	1,455 +264	+22%	+$16K	﹤0.01%	12755
2023 Q1	$93K	Buy	1,191 +250	+27%	+$28.9K	﹤0.01%	11366
2022 Q4	$78.3K	Buy	941 +53	+6%	+$4.26K	﹤0.01%	11553
2022 Q3	$82K	Buy	888 +2	+0.2%	+$258	﹤0.01%	11263
2022 Q2	$133K	Sell	886 -53	-6%	-$9.67K	﹤0.01%	11105
2022 Q1	$228K	Buy	939 +439	+88%	+$115K	﹤0.01%	11218
2021 Q4	$151K	Sell	500 -635	-56%	-$203K	﹤0.01%	12249
2021 Q3	$469K	Buy	1,135 +21	+2%	+$7.31K	﹤0.01%	10032
2021 Q2	$341K	Buy	1,114 +893	+404%	+$196K	﹤0.01%	10963
2021 Q1	$45K	Buy	+221	New	+$48.3K	﹤0.01%	12944

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors's PVLA Position: Q1 2026 in Review

Citadel Advisors increased its Palvella Therapeutics (PVLA) stake by 677% in Q1 2026, buying an estimated $1.86M and bringing the position to 20,472 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #5578.

Citadel Advisors first reported a position in PVLA in Q4 2017 and has held it in 30 quarters since. The position peaked at $11.9M in Q3 2021. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

Citadel Advisors held 20,472 shares of Palvella Therapeutics worth $2.55M as of Q1 2026.
Citadel Advisors bought 17,836 Palvella Therapeutics shares in Q1 2026, an estimated $1.86M.
Palvella Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5578 holding.
Citadel Advisors first reported a position in Palvella Therapeutics in Q4 2017 and has held it in 30 quarters since.
Citadel Advisors's Palvella Therapeutics position peaked at $11.9M in Q3 2021.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.